5452-98-2

Basic information

• Product Name: (2E)-1-(2,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one
• Synonyms: 2-propen-1-one, 1-(2,6-dimethoxyphenyl)-3-phenyl-, (2E)-
• CAS NO: 5452-98-2
• Molecular Formula: C₁₇H₁₆O₃
• Molecular Weight: 268.3071
• Mol File: 5452-98-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 446.1°C at 760 mmHg
• Flash Point: 215.5°C
• Density: 1.128g/cm³
• Vapor Pressure: 3.76E-08mmHg at 25°C
• Refractive Index: 1.591
• CAS DataBase Reference: (2E)-1-(2,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-1-(2,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one(5452-98-2)
• EPA Substance Registry System: (2E)-1-(2,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one(5452-98-2)

Safety Data

• Hazardous Substances Data: 5452-98-2(Hazardous Substances Data)

Usage

Description

(2E)-1-(2,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one, also known as chalcone, is a chalcone compound with the molecular formula C17H16O3. It is a yellow crystalline powder with a molecular weight of 268.31 g/mol. Chalcones are aromatic ketones formed by the combination of a benzaldehyde and an acetophenone.

Uses

Used in Pharmaceutical Synthesis:
(2E)-1-(2,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one is used as an intermediate in the synthesis of pharmaceuticals. It serves as a key building block for the development of various drugs due to its unique chemical structure and properties.
Used in Antioxidant Applications:
In various plant sources, (2E)-1-(2,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one exhibits antioxidant properties. It helps protect cells from oxidative damage caused by free radicals, contributing to the maintenance of overall health and well-being.
Used in Antimicrobial Applications:
This chalcone compound also demonstrates antimicrobial properties, making it useful in the development of antimicrobial agents. It can be employed to combat various types of bacteria and other microorganisms, contributing to the prevention and treatment of infections.
Used in Anticancer Applications:
(2E)-1-(2,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one has been found to possess anticancer properties. It can be used in the development of cancer treatments, potentially targeting and inhibiting the growth of cancer cells, and offering a promising avenue for cancer therapy research.

Upstream product

• 2040-04-2 2,6-dimethoxyacetophenone 
• 100-52-7 benzaldehyde 

Relevant articles and documents

A synthetic chalcone as a potent inducer of glutathione biosynthesis

Chalcones continue to attract considerable interest due to their anti-inflammatory and antiangiogenic properties. We recently reported the ability of 2′,5′-dihydroxychalcone (2′,5′-DHC) to induce both breast cancer resistance protein-mediated export of glutathione (GSH) and c-Jun N-terminal kinase-mediated increased intracellular GSH levels. Herein, we report a structure-activity relationship study of a series of 30 synthetic chalcone derivatives with hydroxyl, methoxyl, and halogen (F and Cl) substituents and their ability to increase intracellular GSH levels. This effect was drastically improved with one or two electrowithdrawing groups on phenyl ring B and up to three methoxyl and/or hydroxyl groups on phenyl ring A. The optimal structure, 2-chloro-4′,6′-dimethoxy-2′- hydroxychalcone, induced both a potent NF-E2-related factor 2-mediated transcriptional response and an increased formation of glutamate cysteine ligase holoenzyme, as shown using a human breast cancer cell line stably expressing a luciferase reporter gene driven by antioxidant response elements.

NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER

Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.